{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Pormohammad A"],"funding":["EC | European Regional Development Fund (ERDF)","Canadian Government | Natural Sciences and Engineering Research Council of Canada (NSERC)","EC | European Regional Development Fund","Canadian Government | Natural Sciences and Engineering Research Council of Canada"],"pagination":["e0007124"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11237694"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["12(6)"],"pubmed_abstract":["Novel antimicrobial agents are needed to combat antimicrobial resistance. This study tested novel pentafluorosulfanyl-containing triclocarban analogs for their potential antibacterial efficacy. Standard procedures were used to produce pentafluorosulfanyl-containing triclocarban analogs. Twenty new compounds were tested against seven Gram-positive and Gram-negative indicator strains as well as 10 clinical isolates for their antibacterial and antibiofilm activity. Mechanistic investigations focused on damage to cell membrane, oxidizing reduced thiols, iron-sulfur clusters, and oxidative stress to explain the compounds' activity. Safety profiles were assessed using cytotoxicity experiments in eukaryotic cell lines. Following screening, selected components had significantly better antibacteria"],"journal":["Microbiology spectrum"],"pubmed_title":["Novel pentafluorosulfanyl-containing triclocarban analogs selectively kill Gram-positive bacteria."],"pmcid":["PMC11237694"],"funding_grant_id":["PID2021-122116OB-I00","Natural Sciences Engineering Research Council of Canada","Canada Research Chair"],"pubmed_authors":["Vazquez S","Zarei M","Turner RJ","Pormohammad A","Pujol E","Naesens L","Hommes JW","Vazquez-Carrera M","Surewaard BGJ","Moradi M"],"additional_accession":[]},"is_claimable":false,"name":"Novel pentafluorosulfanyl-containing triclocarban analogs selectively kill Gram-positive bacteria.","description":"Novel antimicrobial agents are needed to combat antimicrobial resistance. This study tested novel pentafluorosulfanyl-containing triclocarban analogs for their potential antibacterial efficacy. Standard procedures were used to produce pentafluorosulfanyl-containing triclocarban analogs. Twenty new compounds were tested against seven Gram-positive and Gram-negative indicator strains as well as 10 clinical isolates for their antibacterial and antibiofilm activity. Mechanistic investigations focused on damage to cell membrane, oxidizing reduced thiols, iron-sulfur clusters, and oxidative stress to explain the compounds' activity. Safety profiles were assessed using cytotoxicity experiments in eukaryotic cell lines. Following screening, selected components had significantly better antibacteria","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Jun","modification":"2025-04-19T20:07:31.11Z","creation":"2025-04-19T20:07:31.11Z"},"accession":"S-EPMC11237694","cross_references":{"pubmed":["38700321"],"doi":["10.1128/spectrum.00071-24"]}}